Sutro Biopharma earnings were -$180.6M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest STRO earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$38.5M, up 0.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, STRO reported annual earnings of -$191.1M, with -16% growth.
What were Sutro Biopharma's earnings last quarter?
On STRO's earnings call on Aug 13, 2026, Sutro Biopharma (NASDAQ: STRO) reported Q2 2026 earnings per share (EPS) of -$2.33, up 72.59% year over year. Total STRO earnings for the quarter were -$38.53 million. In the same quarter last year, Sutro Biopharma's earnings per share (EPS) was -$1.35.
As of the last Sutro Biopharma earnings report, Sutro Biopharma is currently losing money. Sutro Biopharma's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$180.64 million, a 13.45% decrease year over year.
What was STRO's earnings growth in the past year?
As of Sutro Biopharma's earnings date in Aug 13, 2026, Sutro Biopharma's earnings has grown year over year. STRO earnings in the past year totalled -$180.64 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.